Borel-
Wanted to round back and thank you for the post. You laid out a compelling outline of testing parameters that would help Lero. If one of these agencies would look at the entire catalogue of tested patients, nobody can doubt the safety and in most cases the efficacy....notwithstanding there are next to zero SAE’s attributed to Leronlimab.
For some reason, we have not been able to capture an audience that appreciates that information. I don’t know why: could be the messaging, could be the messenger. Either way, the simplicity in which you lay it out so a layman can understand shows me this isn’t your first rodeo. Kudos!!
I don’t think we will have an immediate answer from the UK meeting, nor do I think they’ll give EUA while it’s still in the review phase with FDA. I do hope that the FDA uses your logic when interim results for CD12 are released and if the primary endpoint (death) shows superior results with Leronlimab that they won’t require further testing.
Look forward to more posts from you!
Grip
News 
Market Data 
Discover 
